The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue
Our study shows that relugolix significantly increases fatigue, affecting multiple areas of life. While the fatigue does not appear to generally impact a patient's ability to carry out normal activities, patients demonstrate frustration with being too tired for these activities. It is essential for clinicians to counsel prostate cancer patients on the impact of neoadjuvant relugolix on quality-of-life issues like fatigue.
Authors
- Malika Danner
- Sarthak Shah (ORCID: https://orcid.org/0000-0002-6979-1416)
- Simeng Suy
- Lindsey Gallagher
- Marilyn Ayoob
- Jessica Hsueh
- Sean P. Collins (ORCID: https://orcid.org/0000-0002-2305-9836)
- Min Ji Koh (ORCID: https://orcid.org/0009-0004-1950-3860)
- Alan Zwart (ORCID: https://orcid.org/0000-0001-6834-9290)
- Paul Leger
- Deepak Kumar (ORCID: https://orcid.org/0000-0002-0418-5116)
- Nancy A. Dawson
Institutions
- North Carolina Central University (US)
- Georgetown University (US)
- MedStar Georgetown University Hospital (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-12
- DOI
- https://doi.org/10.3389/fonc.2024.1412786
- Citations
- 3
- Primary Topic
- Cancer survivorship and care
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Georgetown University
- Accuray
- National Institute on Minority Health and Health Disparities